<DOC>
	<DOC>NCT00437463</DOC>
	<brief_summary>To evaluate the efficacy of the ACE inhibitor ramipril in the treatment of early IgA nephropathy.</brief_summary>
	<brief_title>Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin A</mesh_term>
	<criteria>biopsyconfirmed IgA nephropathy proteinuria less than 0.5 g per day, normal blood pressure, and serum creatinine below 120 Âµmol/l pregnant or nursing mother, or women of childbearing potential without an effective method of birth control history of myocardial infarction, congestive heart failure, or any other medical indication that necessitate the use of ACE inhibitor evidence of clinically significant hepatic, gastrointestinal, autoimmune disease history of malignancy, drug or alcohol abuse participation in any previous trial on ACE inhibitor taking other investigational drugs within the past 30 days known history of sensitivity / allergy to ACE inhibitor The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>